Top 15 Companies in Acute Myeloid Leukaemia Biomarker Testing Market: Statistics Report Till 2035
RELEASE DATE: Mar 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Description
According to a research report published by Spherical Insights & Consulting, The Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size is projected to Grow from USD 371.5 Million in 2024 to USD 924.7 Million by 2035, at a CAGR of 8.64% during the forecast period of 2024–2035. The market is driven by increasing government initiatives aimed at improving cancer diagnostics, such as funding programs by health departments and regulatory frameworks that encourage early disease detection, are catalyzing market expansion
Introduction
The acute myeloid leukemia biomarker testing market consists of laboratory tests, diagnostic kits, and assays used to identify specific genetic mutations, molecular markers, or cellular characteristics in blood or bone marrow samples. Acute myeloid leukemia (AML) is a cancer that originates in the bone marrow and spreads to other parts of the body. The condition of acute myeloid leukemia (AML) arises from an accumulation of immature white blood cells (WBCs), which are known as myeloblasts or leukemic blasts. Biomarker testing functions as an essential diagnostic and treatment tool for AML because it delivers crucial data about the inherited characteristics of the disease.
In November 2025, Servier India, which operates as a subsidiary of French pharmaceutical company Servier Group, introduced its patient-centric biomarker testing program through its partnership with MedGenome and Strand Life Sciences, two leading genomic laboratories. Foundation Medicine, Inc. has partnered with Syndax Pharmaceuticals to create a companion diagnostic test that will detect acute myeloid leukemia patients who possess NPM1 genetic mutations.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the acute myeloid leukemia biomarker testing market.
Acute Myeloid Leukemia Biomarker Testing Market Size & Statistics
- The Market Size for Global Acute Myeloid Leukemia Biomarker Testing was Estimated to be worth USD 371.5 million in 2024.
- The Market is Going to Expand at a CAGR of 8.64% between 2024 and 2035.
- The Global Acute Myeloid Leukemia Biomarker Testing Market Size is anticipated to reach USD 924.7 million by 2035.
- North America is expected to generate the highest demand during the forecast period in the global Acute Myeloid Leukemia Biomarker Testing market.
- Asia Pacific is expected to grow the fastest during the forecast period in the Global Acute Myeloid Leukemia Biomarker Testing Market.
Regional growth and demand
North America is expected to grow the largest during the forecast period in the global acute myeloid leukemia biomarker testing market. North America is expected to grow due to the high prevalence of AML, with an established healthcare infrastructure and strong reimbursement systems, creates conditions that enable this medical facility to achieve its current level of performance. The region will experience market growth because of its existing healthcare and life science industries, with its early adoption of cutting-edge technologies.
Asia Pacific is expected to generate the fastest demand during the forecast period in the global acute myeloid leukemia biomarker testing market. Asia Pacific is expected to grow due to increasing healthcare expenditure and rising awareness of advanced diagnostic techniques. Latin America and Africa represent relatively smaller markets due to limited healthcare resources and affordability challenges. A surge in the incidence of AML and growth in government funding for R&D in disease diagnosis and treatment are anticipated to fuel market statistics in the region in the next few years.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the acute myeloid leukemia biomarker testing market.
Top 10 Trends in the Acute Myeloid Leukemia Biomarker Testing Market
- Dominance of PCR Technology
- Surge in Next-Generation Sequencing (NGS)
- Targeted Therapy Biomarkers
- Rising Importance of MRD Testing
- Focus on TP53 and RUNX1 for Risk Stratification
- Growth in Liquid Biopsy/Blood-Based Testing
- Advancements in Companion Diagnostics
- Expansion of Flow Cytometry for Immunophenotyping
- Integration of AI in Data Interpretation
- Increasing Demand in Emerging Markets
1. Dominance of PCR Technology
The Polymerase Chain Reaction (PCR) technology segment is projected to hold the largest market share during the forecast period. PCR is the current gold standard for measurable residual disease (MRD) testing due to its high sensitivity and rapid turnaround times. The emergence of Droplet Digital PCR (ddPCR) is gaining traction for offering absolute quantification without the need for a standard curve, making it easier to standardize across laboratories.
2. Surge in Next-Generation Sequencing (NGS)
NGS is rapidly becoming an integral component of AML work-up, with testing rates in some cohorts rising from 9% in 2015 to 77% by 2020. NGS can analyze dozens of genes simultaneously, providing a comprehensive view of clonal heterogeneity and identifying multiple actionable mutations at once. Recent European Leukemia Net and WHO updates have established NGS-based profiling as an industry standard for diagnosis and risk stratification.
3. Targeted Therapy Biomarkers
The discovery of specific genetic drivers has led to the development of several FDA-approved targeted therapies. Targeted by Venetoclax (Venclexta), often used in combination with hypomethylating agents (HMA) for elderly or unfit patients. The approval of these drugs has created a lucrative market for companion diagnostic tests that match patients to the correct therapy.
4. Rising Importance of MRD Testing
Measurable Residual Disease has emerged as the strongest independent predictor of relapse and overall survival in AML. The FDA and EMA have issued guidance for using MRD as a surrogate endpoint in clinical trials, which can significantly accelerate the approval process for new drugs. Clinical practice is moving toward MRD-guided therapy, where treatment may be intensified for patients who remain MRD-positive after initial therapy
5. Focus on TP53 and RUNX1 for Risk Stratification
Mutations in TP53 and RUNX1 are critical for defining high-risk subgroups. Associated with extreme therapeutic refractoriness and poor survival (median 2–10 months). It often signifies a complex karyotype and resistance to standard intensive chemotherapy and Venetoclax.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the global acute myeloid leukemia biomarker testing market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the acute myeloid leukemia biomarker testing market.
Top 15 Companies Leading the Acute Myeloid Leukemia Biomarker Testing Market
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific, Inc.
- Abbott Laboratories
- QIAGEN N.V.
- Danaher Corporation
- NeoGenomics Laboratories
- Agilent Technologies, Inc
- Guardant Health, Inc.
- Laboratory Corporation of America Holdings
- Bio-Rad Laboratories, Inc.
- Illumina, Inc.
- Siemens Healthineers AG
- Myriad Genetics, Inc.
- PerkinElmer, Inc
- Foundation Medicine, Inc.
- Other
1. F. Hoffmann-La Roche Ltd.
Headquarters: Basel, Switzerland
F. Hoffmann-La Roche Ltd. is a global biotechnology and pharmaceutical company headquartered in Basel, Switzerland. The company is one of the world’s leading healthcare innovators, focusing on pharmaceuticals and diagnostics. Roche specializes in therapeutic areas such as oncology, immunology, infectious diseases, neuroscience, and ophthalmology. Roche invests heavily in research and development and collaborates with biotechnology firms worldwide to develop advanced medicines and personalized healthcare solutions, aiming to improve patient outcomes and address major global health challenges.
2. Thermo Fisher Scientific, Inc.
Headquarters: Waltham, Massachusetts
Thermo Fisher Scientific, Inc. is a global leader in scientific research services, life sciences solutions, and laboratory equipment. Thermo Fisher provides a wide range of products and services, including analytical instruments, diagnostic tools, laboratory reagents, and pharmaceutical development services. The company serves pharmaceutical, biotechnology, healthcare, academic, and government institutions worldwide. Through continuous innovation, strategic acquisitions, and strong research capabilities.
3. Abbott Laboratories
Headquarters: Abbott Park, Illinois, United States
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, United States. The company focuses on developing a wide range of healthcare products, including diagnostics, medical devices, nutrition products, and branded generic pharmaceuticals. Abbott is well known for its innovations in diagnostic testing, cardiovascular devices, diabetes care systems, and infant nutrition products. The company operates in more than 160 countries and serves hospitals, laboratories, and healthcare providers worldwide.
4. QIAGEN N.V.
Headquarters: Venlo, Netherlands
QIAGEN N.V. is a global provider of molecular diagnostics, life science research tools, and sample technologies. The company was founded in 1984 and focuses on developing technologies that enable the analysis of DNA, RNA, and proteins. QIAGEN’s products are widely used in clinical diagnostics, pharmaceutical research, and academic laboratories. The company offers solutions for disease detection, genetic testing, infectious disease diagnosis, and personalized medicine.
5. Danaher Corporation
Headquarters: Washington, D.C., United States
Danaher Corporation is a multinational conglomerate headquartered in Washington, D.C., United States. The company focuses on life sciences, diagnostics, and environmental and applied solutions. Danaher operates through several well-known subsidiaries, including Beckman Coulter, Cepheid, and Pall Corporation. These businesses provide advanced diagnostic technologies, laboratory instruments, and bioprocessing solutions used by hospitals, research institutions, and pharmaceutical companies worldwide.
Are you ready to discover more about the acute myeloid leukemia biomarker testing market?
The report provides an in-depth analysis of the leading companies operating in the global acute myeloid leukemia biomarker testing market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the acute myeloid leukemia biomarker testing market.
Company Profiles
1. F. Hoffmann-La Roche Ltd.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
2. Thermo Fisher Scientific, Inc.
3. Abbott Laboratories
4. QIAGEN N.V.
5. Danaher Corporation
6. NeoGenomics Laboratories
7. Agilent Technologies, Inc
8. Guardant Health, Inc.
9. Laboratory Corporation of America Holdings
10. Bio-Rad Laboratories, Inc.
Our Reports:
https://www.sphericalinsights.com/reports/europe-anti-aging-supplements-market
https://www.sphericalinsights.com/reports/europe-ophthalmic-drugs-market
https://www.sphericalinsights.com/reports/europe-methanol-market
https://www.sphericalinsights.com/reports/germany-asphalt-pavers-market
https://www.sphericalinsights.com/reports/france-fertility-services-market
Conclusion
The global acute myeloid leukemia biomarker testing market is driven by the rising incidence of leukemia, increasing adoption of advanced molecular diagnostics, and growing demand for personalized cancer treatment. Leading healthcare and diagnostics companies are playing a crucial role in advancing biomarker testing technologies and expanding global diagnostic capabilities. Their investments in research, strategic collaborations, and product innovation are strengthening the competitive landscape of the market. North America dominates the market due to its advanced healthcare infrastructure, strong presence of diagnostic companies, and early adoption of innovative testing technologies. Meanwhile, the Asia-Pacific region is expected to experience the fastest growth because of increasing healthcare spending, expanding diagnostic laboratories, and rising awareness of early cancer detection.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?